Arrowstreet Capital Limited Partnership Has $830.53 Million Stock Position in Danaher Corporation $DHR

Arrowstreet Capital Limited Partnership boosted its position in shares of Danaher Corporation (NYSE:DHR) by 3.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,628,052 shares of the conglomerate’s stock after purchasing an additional 109,039 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Danaher were worth $830,534,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DHR. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter valued at $25,000. Elevated Capital Advisors LLC acquired a new stake in Danaher during the fourth quarter valued at $26,000. WFA of San Diego LLC acquired a new stake in Danaher during the second quarter valued at $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher during the third quarter valued at $27,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in Danaher during the fourth quarter valued at $27,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $179.95 on Friday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock’s 50-day moving average is $180.93 and its two-hundred day moving average is $204.78. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The firm has a market cap of $127.37 billion, a P/E ratio of 34.81, a price-to-earnings-growth ratio of 2.40 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.88 earnings per share. On average, analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. Danaher’s payout ratio is presently 30.95%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DHR. DZ Bank began coverage on Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Argus cut their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Barclays cut their target price on Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Royal Bank Of Canada began coverage on Danaher in a report on Thursday, May 14th. They set an “outperform” rating and a $200.00 target price on the stock. Finally, JPMorgan Chase & Co. cut their target price on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $233.61.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.